Approval

Asserting Internet marketing Approval for Hunterase ICV Injection 15 mg, the World’s First Enzyme Substitute Treatment for Mucopolysaccharidosis Type II (Hunter Syndrome) Administered by ICV Injection

Tanya J. Montague 4 years ago

GC Pharma (previously recognised as Inexperienced Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical business, and Clinigen K.K. (“Clinigen”), headquartered in Tokyo, has received on January 22, 2021, Japan production and advertising and marketing acceptance for Hunterase ICV (intracerebroventricular) Injection 15 mg (generic identify: idursulfase-beta (recombinant)) as a treatment method […]